Management of moderate to severe plaque psoriasis (part I): Clinical update on antitumor necrosis factor agents

Journal of Drugs in Dermatology

Volumn 8, Issue 2, 2009, Pages 147-154

  Sobell, Jeffrey M ^a,b   Kalb B, Robert E ^c   Weinberg, Jeffrey M ^d  

^a TUFTS MEDICAL CENTER   (United States)

^b SKINCARE PHYSICIANS   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; LIVE VACCINE; METHOTREXATE; PLACEBO; TGAAC 94; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC REACTION; ANAPHYLAXIS; ARTHRALGIA; BASAL CELL CARCINOMA; BLOOD TOXICITY; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DEMYELINATING DISEASE; DEMYELINATION; DISEASE CONTROL; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; EDEMA; ESOPHAGUS CANDIDIASIS; FACE EDEMA; HAND EDEMA; HEART FAILURE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYPERSENSITIVITY REACTION; INFECTION; LIP DISEASE; LIP EDEMA; LIVER DISEASE; LOW DRUG DOSE; LUPUS LIKE SYNDROME; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; MELANOMA; MYALGIA; MYCOSIS; NEUROPATHY; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRURITUS; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETREATMENT; REVIEW; RHINOPHARYNGITIS; SEIZURE; SEPSIS; SIDE EFFECT; SORE THROAT; SQUAMOUS CELL CARCINOMA; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TUBERCULOSIS; URTICARIA; VIRUS REACTIVATION; DRUG ANTAGONISM; HOSPITALIZATION; IMMUNOLOGY; PATHOPHYSIOLOGY;

ANTI-INFLAMMATORY AGENTS; HUMANS; PSORIASIS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 62449263854     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. National Psoriasis Foundation. About psoriasis: statistics. National Psoriasis Foundation 2006. Available at: http://www.psoriasis.org/about/ stats/.
2. Thomas VD, Yang FC, Kvedar JC. Biologics in psoriasis: a quick reference guide. J Am Acad Dermatol. 2005;53:346-351. (Pubitemid 40979599)
3. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401-407. (Pubitemid 29418506)
4. Tristani-Firouzi P, Krueger GG. Efficacy and safety of treatment modalities for psoriasis. Cutis. 1998 February;61(2 suppl):11-21.
5. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002;46:1-23. (Pubitemid 34073472)
6. Horn EJ, Patel V, Fox K, Dann F. Treatment patterns and utilization of systemic and biologic therapy among psoriasis patients. J Am Acad Dermatol. 2007;56:272-275.
7. Papp KA, Keystone EC, Shear NH. Mechanism of action, pharmacokinetics, and drug interactions of etanercept in dermatology. J Cutan Med Surg. 2007;11(suppl 1):S3-S13.
8. Rigby WF. Drug Insight: Different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior? Nat Clin Pract Rheumatol. 2007;3:227-233. (Pubitemid 46860407)
9. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-2022. (Pubitemid 37448924)
10. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304-1312. (Pubitemid 40933433)
11. Enbrel (etanercept). [Prescribing information.] Thousand Oaks, CA: Immunex Corporation; April 2006.
12. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627-1632. (Pubitemid 37523083)
13. Elewski B, Leonardi C, Gottlieb AB, et al. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. Br J Dermatol. 2007;156:138-142. (Pubitemid 44924157)
14. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264-2272. (Pubitemid 38924405)
15. Mease P. Psoriatic arthritis update. Bull NYU Hosp Jt Dis. 2006;64:25- 31.
16. Tyring S, Poulin Y, Langley TF. Safety and efficacy profiles of etanercept for up to 144 weeks in patients with moderate to severe plaque psoriasis. Presented at: American Academy of Dermatology Annual Meeting; February 2-6, 2007; Washington, DC.
17. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143:719-726. (Pubitemid 46955730)
18. Gordon K, Leonardi CL, Gottlieb AB. Safety of long-term etanercept treatment in patients with moderate to severe plaque psoriasis: an integrated, multistudy analysis. Presented at: Summer Meeting of the American Academy of Dermatology; August 1-5, 2007; New York, NY.
19. Ahmad K, Rogers S. Two years of experience with etanercept in recalcitrant psoriasis. Br J Dermatol. 2007;156:1010-1014. (Pubitemid 46642862)
20. Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007;56:598-603. (Pubitemid 46400183)
21. Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358:241-251.
22. Remicade (infliximab) for IV injection. [Prescribing information]. Malvern, PA: Centocor, Inc.; April 2007.
23. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51:534-542. (Pubitemid 39278071)
24. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367-1374. (Pubitemid 41443403)
25. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357:1842-1847. (Pubitemid 32539117)
26. Menter A, Guzzo C, Li S, Gottlieb AB. Efficacy of infliximab in patients with severe psoriasis: subgroup analysis from clinical trials. Presented at: American Academy of Dermatology Annual Meeting; February 2-6, 2007; Washington, DC.
27. Rich P, Guzzo C, Li S, Reich K. Nail psoriasis improvement is maintained in patients with moderate to severe psoriasis treated with infliximab. Presented at: American Academy of Dermatology Annual Meeting; February 2-6, 2007; Washington, DC.
28. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56.
29. Giunta A, Papoutsaki M, Bianchi L, Chimenti S. Efficacy and safety of infliximab in long-term treatment of plaque-type psoriasis: a comparative retrospective study on two different (continuous vs. relapse related) regimens. Presented at: American Academy of Dermatology Annual Meeting; February 2-6, 2007; Washington, DC.
30. Haitz KA, Kalb RE. Infliximab in the treatment of psoriasis in patients previously treated with etanercept. J Am Acad Dermatol. 2007;57:120-125. (Pubitemid 46899280)
31. Calabrese LH. Molecular differences in anticytokine therapies. Clin Exp Rheumatol. 2003;21:241-248. (Pubitemid 36519574)
32. Van De Putte LB, Salfeld F, Kaymakcalan Z. Adalimumab. In: Moreland LW, Emery P, eds. TNF-Inhibition in the Treatment of Rheumatoid Arthritis. London: Martin Dunitz; 2003:71-93.
33. Humira (adalimumab). [Prescribing information.] North Chicago, IL: Abbott Laboratories; February 2007.
34. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double- blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598-606. (Pubitemid 44436647)
35. Menter A, Papp KA, Leonardi CL, et al. Short- and long-term efficacy and safety of adalimumab in a pivotal phase III study in adult patients with moderate to severe chronic plaque psoriasis. Presented at: American Academy of Dermatology Annual Meeting; February 2-6, 2007; Washington, DC.
36. Saurat J, Langley R, Stingl G, McIlraith MJ. Adalimumab treatment is associated with more rapid improvement in patients with moderate to severe psoriasis compared with methotrexate and with placebo: results from CHAMPION. Presented at: Summer Meeting of the American Academy of Dermatology; August 1-5, 2007; New York, NY.
37. Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol. 2007;34:1040-1050. (Pubitemid 46774851)
38. Papoutsaki M, Chimenti S, Talamonti M, Chimenti MS. Long-term efficacy of adalimumab for the treatment of psoriasis and psoriatic arthritis. Presented at: American Academy of Dermatology Annual Meeting; February 2-6, 2007; Washington, DC.
39. Pitarch G, Sanchez-Carazo JL, Mahiques L, et al. Treatment of psoriasis with adalimumab. Clin Exp Dermatol. 2007;32:18-22. (Pubitemid 46006359)
40. Reich K. Safety and efficacy of subcutaneous certolizumab pegol, a new anti-TNFa monoclonal antibody, in patients with moderate-to-severe chronic plaque psoriasis: preliminary results from a double-blind, placebo-controlled trial. Presented at: American Academy of Dermatology Annual Meeting; February 2-6, 2007; Washington, DC.